Last updated: 11/04/2018 05:22:15

Bioequivalence study of SB797620 in Healthy Japanese volunteers

GSK study ID
AVR110549
Clinicaltrials.gov ID
NCT00549263
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Withdrawn
Withdrawn
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Bioequivalence Study with a Combination Tablet Formulation of rosiglitazone (RSG) and glimepiride (GLIM)(4mg/2mg) Compared to Concomitant Dosing of RSG 4mg Tablet and GLIM 1mg Commercial Tablet x 2 (4mg+2mg) in Japanese Healthy Male Subjects
Trial description: This study will test whether the Drug levels in plasma after combination formulation tablet dosing (SB797620) and separate formulation tablets dosing (rosiglitazone and glimepiride) to Japanese Healthy volunteer would be the same or not.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Drug levels on Day 1

Timeframe: Day 1

Secondary outcomes:

Adverse events on Day 1

Timeframe: Day 1

Clinical laboratory test on Day 1

Timeframe: Day 1

Vital signs and 12-lead ECG on Day 1

Timeframe: Day 1

Interventions:
Drug: SB797620
Enrollment:
0
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Healthy Subjects
Product
rosiglitazone/glimepiride
Collaborators
Not applicable
Study date(s)
March 2008 to April 2008
Type
Interventional
Phase
1

Participation criteria

Sex
Male
Age
20 - 55 years
Accepts healthy volunteers
Yes
  • Healthy subjects
  • They are Japanese males.
  • The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
  • Known hepatic or biliary abnormalities such as Gilbert’s syndrome.
Inclusion and exclusion criteria
Inclusion criteria:
  • Healthy subjects
  • They are Japanese males.
  • Aged 20 to 55 years, inclusive.
  • They have body mass index at screening within 18.5-25.0. Body weight 50-80kg.
  • AST(GOT), ALT(GPT), gumma-GPT and ALP: below the upper normal range
  • They are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • They could refrain from smoking during hospitalization.
  • They are able to attend all visits and complete the study.
Exclusion criteria:
  • The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
  • Known hepatic or biliary abnormalities such as Gilbert’s syndrome.
  • Use of insulin or oral anti-hyperglycemic agents within the past 3 months prior to screening.
  • Subjects who have a history of lactose intolerance.
  • The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms.
  • The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
  • The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months.
  • The subject has a screening ECG with a QTc value outside the range 320 to 450msec, a PR interval of >230msec and/or a QRS interval of >120msec.
  • The subject has a heart rate outside the range 40 to 110 bpm at screening.
  • The subject has donated a unit of blood ">400mL" within the previous 4 months or ">200mL" within the previous 1 month.
  • The subject is currently taking regular (or a course of) medication (including prescribed drug, over-the-counter medication and herbal remedies), and can not cease them 30 days prior to th first study drug dosing.
  • The subject has a history or current conditions of drug abuse or alcoholism.
  • History of alcohol consumption in the past six months exceeding 7 drinks per week (where 1 drink is 350mL in terms of beer)
  • The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antigen/antibody, HTLV-1 antibody.
  • The subject is positive for urine drug screening.
  • Current history of hypo- or hyperglycemia as indicated by serum glucose values below the laboratory-specified reference range or =110 mg/dL, at screening, or as reported by the subject.
  • History of surgical procedures that might affect the absorption of RSG or GLIM (e.g., partial/total gastrectomy, cholecystectomy).
  • History of hypersensitivity to thiazolidinediones, sulfonylureas or compounds with similar chemical structures.
  • History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to any of the study medications or components thereof.

Trial location(s)

No location data available.

Study documents

No study documents available.

Results overview

Study Results yet to be posted

Recruitment status
Withdrawn
Actual primary completion date
Not applicable
Actual study completion date
Not applicable

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website